India Pharma Outlook Team | Monday, 13 October 2025
Merck, referred to as MSD outside the US and Canada, has declared that it will unveil the latest data concerning its pipeline for HIV treatment and prevention at the 20th European AIDS Conference (EACS 2025), a virtual event from 15 to 18 October 2025, in Paris, France.
At the conference, Merck will have the opportunity to show the results of several important human clinical studies that delineate the innovation strategy of Merck in the field of HIV.
The company will offer additional information obtained from the studies on weight, body composition, fasting lipids, and insulin resistance that accompanied the Phase 3 trials evaluating DOR/ISL against baseline therapy and BIC/FTC/TAF.
Moreover, Merck will provide 96-week safety and pharmacokinetics data from a Phase 2 study of the once-weekly oral combination islatravir and lenacapavir (MK-8591D) as well as Phase 1 results on MK-8527, a novel once-monthly oral HIV PrEP candidate, in adults with renal impairment.
Also Read: Orbital Therapeutics acquired by BMS for $1.5B RNA tech.
Associate Vice President and HIV Section Head, Merck Research Laboratories, Dr. Luisa Stamm, "These comprehensive results across the HIV therapeutic area that are part of our HIV pipeline, with the ongoing FDA review of the Phase 3 DOR/ISL program, are welcome news to all patients and caregivers." "Providing more new and easily adaptable methods for HIV treatment and prevention is our objective."
Merck continues to be the major force in the field of HIV-science working to improve welfare and reduce disease incidence in people living with HIV and those at risk globally.
